<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985527</url>
  </required_header>
  <id_info>
    <org_study_id>CR1389</org_study_id>
    <nct_id>NCT03985527</nct_id>
  </id_info>
  <brief_title>Janus Feasibility Study</brief_title>
  <official_title>Transvenous Nerve Stimulation Study (Janus Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respicardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respicardia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this feasibility study is to assess whether an alternative transvenous lead
      location affects respiration and airway physiology during a commercial remedē® System implant
      procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an acute, prospective, non-randomized, single arm IDE feasibility study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in respiration and airway physiology</measure>
    <time_frame>During procedure (immediately post-stimulation)</time_frame>
    <description>The primary objective is to assess acute changes in respiration and airway physiology during the respiration cycle during a commercial remedē® System implant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <arm_group>
    <arm_group_label>Transvenous nerve stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transvenous nerve stimulation</intervention_name>
    <description>Acute transvenous nerve stimulation during a commercial implant of remedē® System</description>
    <arm_group_label>Transvenous nerve stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years old

          -  Subject with moderate to severe central sleep apnea is undergoing a commercial remedē®
             System implant

          -  Subject is willing and able to give informed consent

        Exclusion Criteria:

          -  Subject is unable or unwilling to participate with study procedures

          -  Subject is pregnant or planning to become pregnant (all women with childbearing
             potential must have a negative pregnancy test within 7 days prior to the remedē system
             implant)

          -  Subject is known to be allergic to radio opaque dye which cannot safely be pre-treated
             per the investigator

          -  Subject has body mass index (BMI) &gt; 40 kg/m2 at the time of implant

          -  Subject has had prior neck surgery

          -  Previous or currently implanted upper airway stimulation device

          -  Subject has had prior oral cavity surgery that may interfere with breathing

          -  Subject has significant upper airway-related anatomic anomaly

          -  Subject is enrolled in concurrent study that may confound the results of this study

          -  Subject is taking muscle relaxant medication unless approved by the site implanter and
             Respicardia clinical staff

          -  Subject has evidence of nerve weakness/paresis/paralysis or a neurologic disorder that
             involves the tongue
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Meyer, MS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Respicardia, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Skorupa</last_name>
    <phone>952-641-4440</phone>
    <email>sskorupa@respicardia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Tucker</last_name>
      <phone>336-718-5889</phone>
    </contact>
    <investigator>
      <last_name>Michael Drucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brougher</last_name>
      <phone>614-292-3962</phone>
    </contact>
    <investigator>
      <last_name>Ralph Augostini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Medical Specialists Association</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Henry</last_name>
      <phone>610-525-1202</phone>
    </contact>
    <investigator>
      <last_name>Sheetal Chandhok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

